Cyclosporin in the treatment of adults with refractory coeliac disease--an open pilot study.
Aliment Pharmacol Ther
; 14(6): 767-74, 2000 Jun.
Article
in En
| MEDLINE
| ID: mdl-10848661
ABSTRACT
AIM:
To evaluate the effect of cyclosporin treatment on clinical and histological parameters in adult patients with refractory coeliac disease.METHODS:
Thirteen patients were treated with oral cyclosporin for 2 months, aiming at serum levels of 100-200 ng/mL. Seven extended medication intake up to a maximum of 12 months. Before and after treatment, clinical parameters were monitored and small intestinal biopsies taken. Ten of 13 patients were typed for HLA-DQA1 and -DQB1 alleles.RESULTS:
Eight of 13 patients responded histologically to cyclosporin treatment. Normalization of villi was demonstrated in five patients, three after prolonged treatment. Eight patients reported a clinical response, of whom six had concomitant histological improvement. No serious side-effects of cyclosporin were noticed. Nine of 10 patients who were immunogenetically typed carried the coeliac disease associated serologic DQ2 markers, one carried neither DQ2 nor DQ8 markers.CONCLUSION:
In our study group of 13 adult refractory coeliac disease patients, cyclosporin in therapeutic doses induced a histological improvement in eight patients (61%), in five of whom (38%) normalization of villi was demonstrated. Thus, we believe that cyclosporin is a therapeutic option in refractory coeliac disease, although we could not confirm earlier reports of unconditional successful treatment.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Celiac Disease
/
Cyclosporine
/
Immunosuppressive Agents
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Aliment Pharmacol Ther
Journal subject:
FARMACOLOGIA
/
GASTROENTEROLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2000
Document type:
Article